urea has been researched along with Prostatic Hyperplasia in 16 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (68.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Byard, RW | 1 |
| Farahani, H | 1 |
| Alaee, M | 1 |
| Amri, J | 1 |
| Baghinia, MR | 1 |
| Rafiee, M | 1 |
| KOSTENKO, SN | 1 |
| FOX, M | 1 |
| PARSONS, FM | 1 |
| Chiu, G | 1 |
| Li, S | 1 |
| Connolly, PJ | 1 |
| Pulito, V | 1 |
| Liu, J | 1 |
| Middleton, SA | 1 |
| Kafetz, K | 1 |
| Upadhyay, L | 1 |
| Tripathi, K | 1 |
| Kulkarni, KS | 1 |
| Willden, EG | 1 |
| Robinson, MR | 1 |
| van Sande, M | 1 |
| Van Camp, K | 1 |
| Di Salle, E | 1 |
| Briatico, G | 1 |
| Giudici, D | 1 |
| Ornati, G | 1 |
| Nesi, M | 1 |
| Panzeri, A | 1 |
| Castro, JE | 1 |
| Griffiths, HJ | 1 |
| Edwards, DE | 1 |
| Vaughan, ED | 1 |
| Gillenwater, JY | 1 |
| Singh, M | 1 |
| Tresidder, GC | 1 |
| Blandy, JP | 1 |
| Lissoos, I | 1 |
| Aubrey, DA | 1 |
| Peeling, WB | 1 |
| Crivda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia[NCT02313233] | 41 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 13.6 | -5.94 |
| Umooze | 9.83 | -3.39 |
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 14.33 | -4.33 |
| Umooze | 11.00 | -9.50 |
It's used to determine the degree of urinary difficulty. (NCT02313233)
Timeframe: 56 days
| Intervention | ml/ sec (Mean) | |
|---|---|---|
| Qmax | Difference of Qmax between V1 and V6 | |
| Placebo | 12.72 | 2.49 |
| Umooze | 14.4 | 2.88 |
The PVR urine test measures the amount of urine left in the bladder after urination. (NCT02313233)
Timeframe: 56 days
| Intervention | ml (Mean) | |
|---|---|---|
| Post- Void Residual Volume (PVR) | Difference of PVR between V1 and V6 | |
| Placebo | 67.2 | 14.8 |
| Umooze | 35.3 | -8.39 |
It's related to progression of benign prostatic hyperplasia (BPH). (NCT02313233)
Timeframe: 56 days
| Intervention | cm^3 (Mean) | |
|---|---|---|
| Prostate Volume | Difference of prostate volume between V1 and V6 | |
| Placebo | 38.2 | -1.33 |
| Umooze | 29.1 | -8.17 |
Serum PSA test measures the amount of prostate- specific antigen in the blood. As a man's prostate enlarges with age, the amount of PSA in the blood normally increases. (NCT02313233)
Timeframe: 56 days
| Intervention | ng/ml (Mean) | |
|---|---|---|
| Prostate- specific Antigen (PSA) | Difference of PSA between V1 and V6 | |
| Placebo | 2.22 | 0.26 |
| Umooze | 1.67 | 0.14 |
The Quality of Life (QoL) is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality of Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.27 | -0.09 |
| Umooze | 2.73 | -0.82 |
The QoL index is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality-of-Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.22 | -0.56 |
| Umooze | 2.72 | -0.61 |
1 review available for urea and Prostatic Hyperplasia
| Article | Year |
|---|---|
Renal impairment in the elderly: a review.
Topics: Acute Kidney Injury; Aged; Aging; Creatinine; Dehydration; Female; Glomerular Filtration Rate; Heart | 1983 |
3 trials available for urea and Prostatic Hyperplasia
| Article | Year |
|---|---|
A study of prostane in the treatment of benign prostatic hyperplasia.
Topics: Aged; Creatinine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Plant Extracts; Prostate-Sp | 2001 |
Plasma zinc legels in prostatic disease.
Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Clinical Trials as Topic; Creatinine; Female; H | 1975 |
A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy.
Topics: Clinical Trials as Topic; Cystoscopy; Factor Analysis, Statistical; Humans; Male; Placebos; Prostati | 1971 |
12 other studies available for urea and Prostatic Hyperplasia
| Article | Year |
|---|---|
Obstructive uropathy and unexpected death.
Topics: Aged; Cachexia; Creatinine; Death, Sudden; Dilatation, Pathologic; Humans; Hydronephrosis; Male; Pro | 2020 |
Serum and Saliva Concentrations of Biochemical Parameters in Men with Prostate Cancer and Benign Prostate Hyperplasia.
Topics: beta 2-Microglobulin; Biomarkers; Case-Control Studies; Creatine Kinase, BB Form; Creatinine; Down-R | 2020 |
[Urea clearance as a kidney function test in prostate adenoma].
Topics: Adenoma; Humans; Kidney Function Tests; Male; Prostatic Hyperplasia; Urea; Urography | 1962 |
INDICATIONS FOR HAEMODIALYSIS IN ADVANCED URAEMIC PROSTATIC OBSTRUCTION.
Topics: Blood Chemical Analysis; Dialysis; Geriatrics; Humans; Kidney; Kidneys, Artificial; Male; Preoperati | 1964 |
(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Prostatic Hyperplasia; Receptors, Adrenergic, | 2008 |
Amino acids of the Krebs-Henseleit cycle of median and lateral lobes in human benign prostatic hypertrophy.
Topics: Amino Acids; Arginine; Citrulline; Humans; Male; Ornithine; Prostate; Prostatic Hyperplasia; Protein | 1978 |
17 beta-acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5 alpha-reductase.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aging; Androstanes; Animals; Az | 1992 |
Diagnosis, characterization and management of post-obstructive diuresis.
Topics: Aged; Creatinine; Desoxycorticosterone; Diuresis; Edema; Heart Failure; Humans; Hypertension; Infusi | 1973 |
The evaluation of transurethral resection for benign enlargement of the prostate.
Topics: Adult; Age Factors; Aged; Epididymitis; Humans; Male; Methods; Middle Aged; Prostatectomy; Prostatic | 1973 |
Simple prostatic hyperplasia in the Bantu.
Topics: Adult; Aged; Black People; Hematuria; Hernia, Inguinal; Humans; Male; Middle Aged; Prostatectomy; Pr | 1973 |
Carcinoma of the prostate. A retrospective analysis of conventional management in 110 cases.
Topics: Acid Phosphatase; Age Factors; Aged; Blood Sedimentation; Diagnosis, Differential; Estrogens; Hemogl | 1973 |
[Forced diuresis in the immediate postoperative period after prostatic adenomectomy].
Topics: Diuretics; Furosemide; Humans; Male; Postoperative Care; Prostatic Hyperplasia; Urea; Water-Electrol | 1974 |